Products with Central nervous system depressant action bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN5080 | Strictosamide |
| 1. Strictosamide may have important effects on inflammation and inflammatory pain. 2. Strictosamide is slightly toxic to Charles River mouse (LD(50)=723.17 mg/kg), producing CNS depression and kidney toxicity. 3. Strictosamide has nonsignificant in vitro and in vivo effect on kidney Na(+),K(+)-ATPase activity but produced an in vivo increase of Na(+),K(+)-ATPase activity of brain. 4. Strictosamide possesses antibacterial and antiviral activities. | |
| BCN5273 | Gardneramine |
| 1. Gardneramine and hirsutine show a local anesthetic action, they also can inhibit the ganglionic transmission of the dog urinary bladder and that the blockade of the nicotinic receptor plays a main role. 2. Gardneramine has a mild central depressive effect. | |
| BCN5298 | Mesuaxanthone A |
| 1. Mesuaxanthone A and mesuaxanthone B are two yellow pigments. 2. Mesuaxantbone A and mesuaxanthone B produce varying degrees of C.N.S. depression characterised by ptosis, sedation, decreased spontaneous motor activity, loss of muscle tone, potentiation of pentobarbitone sleeping time and ether anaerthesia in mice and rats; they also exhibit anti inflammatory activity both by intraperitoneal and oral routes in rats. | |
| BCN5583 | Reticuline |
| Reticuline is a key compound in the biosynthetic pathway for isoquinoline alkaloids in plants, which include morphine, codeine and berberine. Reticuline possesses potent central nervous system depressant action, it (50-100 mg/kg i.p.) can produce alteration of behaviour pattern, prolongation of pentobarbital-induced sleep, reduction in motor coordination and D-amphetamine-induced hypermotility and suppression of the conditioned avoidance response. (S)-Reticuline can elicit vasorelaxation probably due to the blockade of the L-type voltage-dependent Ca(2+) current in rat aorta, the effect may contribute to the potential cardioprotective efficacy of (S)-reticuline. | |
| BCN6706 | Yangambin |
| 1. Yangambin is a selective antagonist of the cardiovascular effects of platelet activating factor (PAF) and therefore constitutes a potential therapeutic agent in different shock states where abnormal PAF release is supposed to play an important role. 2. Yangambin has central nervous system activity, it presents a depressant activity in the open field, forced swimming and pentobarbital sleeping time tests. 3. Yangambin has hypotensive effect, which is probably due to a peripheral vasodilatation that involves, at least, the inhibition the Ca2+ influx through voltage-gated Ca2+ channels. | |
